About RAPT Therapeutics, Inc.
https://www.rapt.comRAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases.
CEO
Brian Russell Wong
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2025-06-17 | Reverse | 1:8 |
ETFs Holding This Stock
Summary
Showing Top 3 of 52
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
HC Wainwright & Co.
Buy
Clear Street
Buy
Leerink Partners
Outperform
JP Morgan
Overweight
Barclays
Overweight
Wells Fargo
Overweight
Grade Summary
Showing Top 6 of 7
Price Target
Institutional Ownership
SVENNILSON PETER
Shares:5.63M
Value:$195.55M
BLACKROCK INC.
Shares:2.44M
Value:$84.74M
TCG CROSSOVER MANAGEMENT, LLC
Shares:1.64M
Value:$56.83M
Summary
Showing Top 3 of 81
About RAPT Therapeutics, Inc.
https://www.rapt.comRAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $19.37M ▲ | $-17.58M ▲ | 0% | $-0.65 ▲ | $-17.38M ▲ |
| Q2-2025 | $0 | $19.34M ▲ | $-17.64M ▼ | 0% | $-0.65 ▼ | $-17.44M ▲ |
| Q1-2025 | $0 | $19.27M ▼ | $-17.16M ▲ | 0% | $-0.64 ▲ | $-19.01M ▲ |
| Q4-2024 | $0 | $54.47M ▲ | $-53.25M ▼ | 0% | $-9.12 ▼ | $-54.18M ▼ |
| Q3-2024 | $0 | $19.79M | $-18.43M | 0% | $-3.79 | $-19.49M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $157.34M ▼ | $165.74M ▼ | $13.76M ▼ | $151.98M ▼ |
| Q2-2025 | $168.95M ▼ | $178.41M ▼ | $14M ▲ | $164.41M ▼ |
| Q1-2025 | $179.28M ▼ | $187.57M ▼ | $10.2M ▼ | $177.37M ▼ |
| Q4-2024 | $231.06M ▲ | $240.32M ▲ | $50.42M ▲ | $189.9M ▲ |
| Q3-2024 | $97.91M | $108.47M | $12.96M | $95.51M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-17.58M ▲ | $-12.46M ▼ | $8.47M ▲ | $36K ▼ | $-3.96M ▲ | $-12.46M ▼ |
| Q2-2025 | $-17.64M ▼ | $-11.27M ▲ | $-7.26M ▲ | $161K ▲ | $-18.37M ▲ | $-11.31M ▲ |
| Q1-2025 | $-17.16M ▲ | $-52.41M ▼ | $-57.06M ▼ | $0 ▼ | $-109.48M ▼ | $-52.46M ▼ |
| Q4-2024 | $-53.25M ▼ | $-10.44M ▲ | $-843K ▼ | $143.12M ▲ | $131.84M ▲ | $-10.44M ▲ |
| Q3-2024 | $-18.43M | $-17.62M | $18.45M | $0 | $823K | $-17.64M |
CEO
Brian Russell Wong
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2025-06-17 | Reverse | 1:8 |
ETFs Holding This Stock
Summary
Showing Top 3 of 52
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
HC Wainwright & Co.
Buy
Clear Street
Buy
Leerink Partners
Outperform
JP Morgan
Overweight
Barclays
Overweight
Wells Fargo
Overweight
Grade Summary
Showing Top 6 of 7
Price Target
Institutional Ownership
SVENNILSON PETER
Shares:5.63M
Value:$195.55M
BLACKROCK INC.
Shares:2.44M
Value:$84.74M
TCG CROSSOVER MANAGEMENT, LLC
Shares:1.64M
Value:$56.83M
Summary
Showing Top 3 of 81